CB1 receptor antagonists have been shown to prevent acute and long-term behavioral effects of cocaine. Here we evaluate the effectiveness of the CB1 receptor antagonist rimonabant to modify sensitized responses to cocaine. Mice were treated with saline or cocaine injections in a 15-day intermittent sensitization treatment and subsequently treated with either vehicle, 1 or 10 mg/kg rimonabant in the drug-associated environment for 8 consecutive days. Animals were then challenged with saline and cocaine in the open-field apparatus on subsequent days to evaluate the expression of conditioned and sensitized effects to cocaine. c-Fos protein expression was evaluated in the nucleus accumbens (NAcc), ventral tegmental area (VTA), basolateral amygdala (BLA), medial prefrontal cortex (mPFC) and caudate-putamen (CPu) after the last (cocaine) challenge. Previous treatment with 10 mg/kg rimonabant blocked the expression of conditioned hyperlocomotion and behavioral sensitization to cocaine, but not acute cocaine-induced hyperlocomotion. These behavioral effects were accompanied by significant changes in c-Fos expression in the brain reward system. Chronic cocaine sensitization blunted a subsequent acute cocaine-induced increase in c-Fos protein in the NAcc, effect that was reversed by previous treatment with rimonabant. Treatment with 10 mg/kg rimonabant also attenuated the significant increase in c-Fos expression in the CPu, mPFC and BLA induced by previous chronic sensitization with cocaine. Our findings add to the evidence that drugs targeting CB1 receptors are good candidates for the treatment of cocaine abuse and provide further insights into the mechanisms underlying endocannabinoid signaling within the brain reward system in the context of cocaine abuse.
Introduction
All psychoactive drugs causing addiction in humans activate the mesocorticolimbic system by increasing dopamine availability in the nucleus accumbens (NAcc) (for review see Koob and LeMoal, 2001 ). This effect, responsible for modulating the reinforcing mechanisms of drugs of abuse in humans, also elicits locomotor stimulation in rodents, with repetitive administration intensifying this response (Stewart and Badiani, 1993) . This phenomenon, called behavioral sensitization, is thought to share neuroadaptations with addiction to drugs of abuse and craving in humans (Robinson and Berridge, 1993) .
Neuroadaptations in the mesocorticolimbic system resulting from repeated drug administration are influenced by associations between the neuropharmacological effects of drugs and the environmental context in which the drugs are being administered (Badiani and Robinson, 2004; Michel et al., 2003) . Through multiple pairings, environmental cues acquire conditioned reinforcing properties via associative learning (Buffalari and See, 2010) , what in the behavioral sensitization paradigm is expressed as a conditioned hyperlocomotion when rodents are exposed to the drug-associated environment in the absence of the drug .
The resulting long-term memories can be responsible for the ability of drug-associated environmental cues to reinstate extinguished drugseeking behavior or to lead to relapse into drug use (Crombag and Shaham, 2002; Everitt et al., 2001) . Therefore, an improved treatment strategy for drug abuse should combine extinction therapy with pharmacotherapy to modulate learning during treatment and prevent relapse. We have previously established a protocol in which therapeutic drugs are administered in the drug-associated context aiming to modify sensitized responses induced by a repeated treatment with drugs of abuse in mice , 2017 .
The search for medications development for cocaine abuse has originally focused on the dopaminergic system. However, most recent investigations have explored other neural systems that play a role in addictive processes. Evidence suggests that endocannabinoids are critically involved in drug addiction (Le Foll and Goldberg, 2005) , with the cannabinoid CB1 receptor participating in drug reward and cue reactivity (Lupica et al., 2004) . These receptors are densely expressed in the mesolimbic dopaminergic pathway (Tsou et al., 1998) , and activation of cannabinoid CB1 receptors is required for the expression of cocaine-induced rewarding effects in rodents (Xi et al., 2008) . In fact, a previous study from our group demonstrated that treatment with the CB1 receptor antagonist rimonabant blocked cocaine-induced hyperlocomotion and behavioral sensitization in mice .
The aim of the present study was to evaluate the effects of the CB1 receptor antagonist rimonabant on a post-sensitization protocol to modify sensitized responses induced by a repeated treatment with cocaine. Given the rapid induction by cocaine of c-Fos protein expression (see Kufahl et al., 2009 and references within), a marker for stimulus-elicited brain activity (Harlan and Garcia, 1998) , we investigated if the post-sensitization treatment with rimonabant would affect the reward circuitry as indicated by modulating cocaine-induced c-Fos expression.
Methods

Animals
Three-month-old Swiss male mice from our own colony were used. Animals weighing 35-40 g were housed under controlled temperature (22-23°C) and light (12 h light, 12 h dark; lights on at 6h45a.m.) conditions. Food and water were available ad libitum throughout the experiments. Animals were maintained according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, revised 1996) . The Institutional Ethical Committee of UNIFESP approved the experimental procedures (protocol #470/07).
Drugs
Cocaine-HCl (Sigma®) was diluted in 0.9% saline solution. Rimonabant (Sanofi-Aventis®) was dissolved in a solution of saline + 1% Tween 80 + 3% propylene glycol, which was used as vehicle solution (Veh). All solutions were administered intraperitoneally at 10 ml/kg of body weight. The selected dose range of rimonabant and cocaine was based on previous studies from our group (Marinho et al., 2014 .
Open-field evaluation
Locomotor activity was measured in an open-field apparatus as described previously (Chinen and Frussa-Filho, 1999) . The apparatus consisted of a circular wooden arena (40 cm in diameter and 50 cm high) with an open top and a floor divided into 19 squares. Handoperated counters were used by an observer who was blind to the treatment to score total locomotion frequencies (total number of any squares entered) during the 10-min sessions.
Experimental procedures
Experiment 1
Effects of rimonabant on a post-sensitization protocol to modify sensitized responses and c-Fos expression induced by a repeated treatment with cocaine.
2.4.1.1. Locomotor activity. Eighty-four male mice were given a 10-min habituation period in the open field on 2 consecutive days after a saline i.p. injection. Basal locomotor activity was measured on day 2. Seven groups of animals were formed (n = 12 for each group), which were statistically equivalent with respect to the basal levels of locomotor activity. Twenty-four hours after the second habituation day, the behavioral sensitization procedure began. Four groups of animals received an i.p. injection of saline (Sal) and the remaining groups were treated with 10 mg/kg cocaine (Coc) 5 min prior to being placed in the open-field apparatus every other day for 15 days (3th to 17th days; Sensitization Phase). During the alternate non-sensitization days, mice were left undisturbed in their home-cages. On days 3 and 17 animals were observed for the quantification of their locomotion frequency.
Forty-eight hours after the last injection of the sensitization phase, the post-sensitization protocol began (19th day). For 8 consecutive days (19th to 26th days) 12 animals from the Sal group received daily saline i.p. injections (Sal-Sal). Another group of 12 animals from the Sal group received daily vehicle i.p. injections (Sal-Veh) and the remaining mice in the Sal group received daily i.p. injections of rimonabant (Rim) at the doses of 1 (Sal-Rim1, n = 12) or 10 mg/kg (Sal-Rim10, n = 12). Cocaine-sensitized groups underwent the same procedure (Coc-Veh, Coc-Rim1 and Coc-Rim10 groups, n = 12 per group). Thirty minutes after each administration of saline, vehicle or rimonabant, animals were individually exposed to the open-field arena for 10-min sessions (PostSensitization Phase). On days 19 and 26 animals were observed for the quantification of their locomotion frequency.
Four days after the last post-sensitization day (30th day), all animals received an i.p. saline injection and were placed in the open-field apparatus 5 min later for locomotion frequency quantification. Two days after the Saline challenge, animals were tested for the expression of cocaine-induced behavioral sensitization (day 32). Except for the SalSal group, which received a saline i.p. injection, all animals received an i.p. injection of 10 mg/kg cocaine and were placed in the open-field apparatus 5 min later for locomotion frequency quantification.
2.4.1.2. c-Fos protein expression. Ninety minutes after the last behavioral test (Cocaine Challenge), 6 animals per group were randomly selected and deeply anesthetised and perfused through the heart with 50 ml of saline solution (9% NaCl) followed by 200 ml of 4% paraformaldehyde at 4°C. The brains were removed and post-fixed in 4% paraformaldehyde for 1 day, and then in isotonic solution of sucrose (30%) to cryoprotection. Brains were then sectioned in cryostat (Leica CM1850). Coronal brain sections (30-μm thick) were made between bregma 1.98 and bregma −3.88 mm, according to the stereotaxic coordinates of the mouse brain atlas. Sections were selected (6 per animal) to quantify the c-Fos expression by immunohistochemistry using rabbit anti-c-Fos (1:3000, Calbiochem) as primary antibody. Freefloating sections were washed in PBS and incubated separately overnight with the primary antibody diluted in PBS. After incubation, the sections were washed in PBS and incubated with biotinylated antirabbit secondary antibody for 2 h (1:600, Vectastain Vector), followed by incubation in the ABC kit solutions (Vectashield, Vector, Burlingame, CA, EUA) for 1.5 h. The sections were stained with diaminobenzidine (DAB, Sigma-Aldrich Corporation, St. Louis, EUA) and mounted on slides and sealed with coverslips. E.A.V. Marinho et al. Pharmacology, Biochemistry and Behavior 156 (2017) 16-23 c-Fos expression was evaluated in the medial prefrontal cortex (mPFC), caudate-putamen (CPu), basolateral amigdala (BLA), NAcc and ventral tegmental area (VTA). The anatomical locations and boundaries of each region were determined using a mouse brain atlas (Paxinos and Franklin, 2004) and are illustrated in Fig. 1 . All slides were examined using a light microscope (Nikon 80i), and images were captured and digitized using the Nikon ACT-1 v.2 system and analyzed with the Image J software. In each section, nuclear profiles of c-Fos cells were counted by an observer blind to the experimental condition. Cells stained for c-Fos were counted under 20 × magnification in 18 random, non-overlapping fields of 0.26 mm 2 per structure of each animal (see Fig. 2 ).
Statistical analysis
All variables were checked for normality (Shapiro-Wilk test) and homogeneity (Levene's test), which validated the use of the parametric tests. The locomotor responses at one time point were analyzed by one-(Habituation) or three-way (Saline and Cocaine challenges) analysis of variance (ANOVA). The locomotor responses on different treatment days were analyzed by two-(Sensitization Phase) or three-way (PostSensitization Phase) repeated measures (RM) ANOVA. Expression of cFos protein in different brain regions was analyzed by three-way ANOVA. For ANOVA analysis, the following factors were considered: time, Cocaine treatment (saline vs cocaine during the Sensitization Phase), Rimonabant treatment (saline, vehicle, 1 mg/kg rimonabant or 10 mg/kg rimonabant during the Post-Sensitization Phase) and Challenge treatment (cocaine vs saline). Multiple comparisons were performed using Tukey's post hoc test. A p value < 0.05 was considered a statistically significant difference.
Results
Experiment 1
Locomotor activity
Analysis of the 2nd habituation session revealed no significant difference between groups [F(6,77) = 0.93; p > 0.05] (one-way ANOVA, data not shown). For the Sensitization Phase, two-way RM ANOVA showed a significant interaction effect between time (1st Day vs On the 8th Day of treatment with rimonabant, Tukey's post hoc test revealed that the locomotor activity presented by the cocaine-treated groups was no longer greater than that of their respective control groups, indicating a complete extinction of the conditioned locomotion to cocaine. Treatment with rimonabant at the highest dose nonselectively inhibited locomotor activity of mice, decreasing locomotion frequency compared to the respective vehicle-treated groups.
During the Saline Challenge, two-way ANOVA showed a significant interaction effect between Cocaine treatment and Rimonabant treatment [F(2,77) = 2.56; p < 0.05]. Tukey's post hoc test revealed the persistence of conditioned locomotion in the cocaine control group (Coc-Veh) and in the group previously sensitized to cocaine and treated with 1 mg/kg rimonabant (Coc-Rim1). Animals from the Sal-Rim10 group presented similar locomotor activity to the Sal-Veh group, demonstrating that the hypolocomotor effect of the highest dose of rimonabant was abolished after rimonabant withdrawal. Animals previously sensitized to cocaine and treated with 10 mg/kg rimonabant did not express conditioned locomotion, showing that rimonabant dosedependently improved extinction rates.
Three-way ANOVA showed a significant effect of Challenge treatment [F(1,83) = 10.04, p < 0.01] and a significant interaction effect between Cocaine treatment and Rimonabant treatment [F(2,77) = 4.72; p < 0.05]. Tukey's post hoc test indicated that animals receiving cocaine for the first time during the Cocaine Challenge showed increased locomotion frequency compared to the control group (Sal-Sal) regardless of previous (vehicle or rimonabant) treatment. Tukey's post hoc test also indicated that the control group previously sensitized to cocaine showed a robust sensitization. Animals previously sensitized to cocaine and treated with the highest dose of rimonabant showed lower locomotion frequency compared to cocaine control animals (Coc-Rim10 < Coc-Veh), not differing from saline-treated groups receiving cocaine for the first time.
Expression of c-Fos
Three-way ANOVA indicated a significant effect of Rimonabant treatment [F(3,36) = 28.01, p < 0.0001] and Challenge treatment [F (1,36) = 55.44, p < 0.0001] on c-Fos counts in the NAcc (Fig. 4A ). Tukey's post hoc test showed that animals receiving an acute cocaine treatment for the first time showed increased c-Fos counts in the NAcc compared to control animals (Sal-Veh > Sal-Sal). The group chronically sensitized to cocaine and subsequently treated with vehicle showed lower c-Fos counts in the NAcc compared to the control group receiving cocaine for the first time (Sal-Veh > Coc-Veh). NAcc c-Fos levels of animals previously sensitized to cocaine and treated with Fig. 2 . Fos-immunoreactive neuronal nuclei in rat nucleus accumbens (NAcc), medial pre-frontal cortex (mPFC), caudate-putamen (CPu) and basolateral amigdala (BLA) following a 10 mg/kg cocaine challenge in acute (Sal-Veh) or chronic (Coc-Veh) cocaine-treated mice and after treatment with 1 or 10 mg/kg rimonabant in chronic cocaine sensitized animals (CocRim1 and Coc-Rim10). Scale Bar = 100 μm.
E.A.V. Marinho et al. Pharmacology, Biochemistry and Behavior 156 (2017) 16-23 rimonabant were similar to those of animals receiving cocaine for the first time (Sal-Veh = Coc-Rim1 and Coc-Rim10 > Coc-Veh). Three-way ANOVA indicated a significant effect of Challenge treatment only [F(1,36) = 26.671, p < 0.0001] on c-Fos counts in the VTA (Fig. 4B ). Tukey's post hoc test showed that all groups challenged with cocaine showed higher c-Fos counts in the VTA compared to the saline control group (Sal-Sal), regardless of previous treatment condition.
Three-way ANOVA indicated a significant interaction effect between Cocaine treatment and Rimonabant treatment [F(2,36) = 18.72, p < 0.0001] on c-Fos counts in the BLA (Fig. 4C) , mPFC [F(2,36) = 3.03, p < 0.05] (Fig. 4D) and CPu [F(2,36) = 12.77, p < 0.0001] (Fig. 4E ). Tukey's post hoc test showed that the number of c-Fos positive cells in the BLA, mPFC and CPu increased in the group previously sensitized to cocaine and subsequently treated with vehicle (Coc-Veh) compared to both the Sal-Sal and the Sal-Veh control groups. Animals previously sensitized to cocaine and treated with the highest dose of rimonabant during the Post-Sensitization Phase showed lower numbers of c-Fos positive cells compared to cocaine control animals (CocRim10 < Coc-Veh), not differing from saline-treated groups. Rimonabant was more effective in decreasing cocaine-induced c-Fos counts in the CPu, reducing the number of positive c-Fos cells at both doses (Fig. 4E ).
Discussion
Because evidence suggested that the cannabinoid CB1 receptor is intrinsically related to drug reward and cue reactivity (Lupica et al., 2004) , in the present study we evaluated the effectiveness of the CB1 receptor antagonist rimonabant in a protocol that involved the administration of the treatment drug in the cocaine-associated environment. Gerdeman et al. (2008) had previously demonstrated that a similar treatment with rimonabant was effective in reversing cocaine-induced behavioral sensitization when given in the testing environment, but not in the home-cage. These data emphasize the involvement of the CB1 receptor in cocaine conditioned reinforcement. Although acute rimonabant treatment had no effects on conditioned cocaine response, indicating that rimonabant may have no initial therapeutic potential, chronic treatment with a high dose of rimonabant in the open-field selectively blocked the subsequent expression of conditioned locomotion to cocaine. This effect was preceded by a non-selective locomotor activity inhibition during the last day of treatment with 10 mg/kg rimonabant. Because behavioral analyses were only conducted on the 1st and last days of the Post-Sensitization Phase, we could not evaluate whether the locomotion decline rates in the Rim10-treated groups were parallel. After a 4-day rimonabant withdrawal, the hypolocomotor effect observed in the vehicle group did not persist and influence the conditioning and cocaine tests. This finding indicates that there were no non-specific carryover effects of the 10 mg/kg rimonabant treatments to the conditioning and cocaine tests. E.A.V. Marinho et al. Pharmacology, Biochemistry and Behavior 156 (2017) 16-23 Previous treatment with rimonabant also prevented the expression of behavioral sensitization to cocaine, but not of acute cocaine-induced hyperlocomotion, in a dose-dependent manner. To further elucidate the neural mechanisms underlying the behavioral effects observed herein, we then evaluated cocaine-induced c-Fos protein expression in the brain of mice after the last cocaine challenge. Immediate early genes, such as c-Fos, and their protein products play an important role in transducing extracellular stimuli into altered patterns of cellular gene expression and into changes in cellular functioning (Sheng and Greenberg, 1990) . Thus, c-Fos is expressed at low levels in the unstimulated brain, being rapidly expressed in certain neuronal systems following exposure to specific stimuli, such as cocaine (Young et al., 1991) .
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It has been previously demonstrated that an acute cocaine challenge increases c-Fos protein expression in the NAcc of rodents (Young et al., 1991) . Importantly, this effect has been associated with the acute psychomotor stimulant effects of cocaine (Uslaner et al., 2001) . In the present study, control animals acutely treated with cocaine for the first time expressed cocaine-induced hyperlocomotion, effect that was accompanied by an increase in c-Fos protein expression in the NAcc. Importantly, acute cocaine-induced hyperlocomotion had the same magnitude as the conditioned cocaine response observed on the 1st day of the post-sensitization treatment. Previous treatment with rimonabant was not effective in attenuating acute cocaine-induced increases in NAcc c-Fos expression. CB1 receptors are highly expressed in most gamma-aminobutyric acid (GABA)ergic inhibitory interneurons in the reward circuitry, including the mPFC, BLA and NAcc, modulating synaptic GABA release (Berghuis et al., 2007; Hájos and Freund, 2002; Piomelli et al., 2000) . Importantly, the stimulation of cortical afferents by endocannabinoids causes long-term depression (LTD) of glutamatergic synapses in the NAcc, phenomenon that is mediated by endocannabinoid release and presynaptic CB1 receptors (Gerdeman et al., 2002; Robbe et al., 2002) . This retrograde LTD in the NAcc is promptly eliminated by an acute cocaine exposure (Fourgeaud et al., 2004) , supporting previous and current findings of high c-Fos expression within the NAcc in acutely cocaine treated animals.
Behavioral sensitization to cocaine, on the other hand, is accompanied by a reduction in basal extracellular glutamate within the NAcc (Pierce et al., 1996) as well as by a decrease in synaptic strength in the NAcc (Thomas et al., 2001) . It has been previously demonstrated that responses of NAcc neurons to glutamate are decreased for at least 14 days after a cocaine sensitization treatment (White et al., 1995) . In addition, Thomas et al. (2001) observed that chronic sensitization with cocaine in mice led to a decrease in AMPA/NMDA receptor-mediated excitatory postsynaptic currents made by prefrontal cortical afferents onto the NAcc shell, suggesting that a LTD-like process in the NAcc may contribute to the mechanisms underlying cocaine-induced behavioral sensitization. Accordingly, because c-Fos protein expression seems to require synaptic activation, thereby representing a measure of synapse strength (Luckman et al., 1994) , in the present study chronic cocaine exposure significantly attenuated the NAcc c-Fos expression induced by an acute Cocaine Challenge. This result is in line with previous findings demonstrating that repeated injections of cocaine cause blunted responses to acute cocaine-induced increases in the expression of immediate early genes, including c-Fos (for review see McCoy et al., 2011) . Of note, treatment with rimonabant at both doses was effective in reversing long-term effects of previous cocaine treatment in NAcc cFos expression. Because CB1 receptors in the cortex mediate endocannabinoid-LTD into the NAcc, CB1 blockade by rimonabant would be expected to reverse this phenomenon, thereby reversing chronic cocaine-induced changes in synapse activation and, consequently, in c-Fos expression within this brain region. Further studies evaluating cFos expression in the NAcc after rimonabant treatments and before cocaine challenge could provide additional insights into this phenomenon.
Animals acutely and chronically treated with cocaine did not differ in VTA c-Fos expression levels, profile that was not affected by previous treatment with rimonabant. Changes on excitatory afferents onto dopamine neurons in the VTA are among the earliest adaptations that can be observed after a first drug exposure (Ungless et al., 2001) . Acute cocaine injection increases intermediate early gene expression in the VTA (Kaufling et al., 2010) . Chauvet et al. (2011) showed that chronic cocaine administration in a conditioned place preference protocol also increased c-Fos expression in the VTA of rats. Thus, in line with previous reports, our results show that opposed to that observed for the NAcc, chronic administration of cocaine during sensitization does E.A.V. Marinho et al. Pharmacology, Biochemistry and Behavior 156 (2017) 16-23 not affect the effects of a subsequent acute cocaine challenge on c-Fos protein expression in the VTA. As previously mentioned, because CB1 receptors seem to be involved in cocaine conditioned reinforcing (Lupica et al., 2004) and treatment with rimonabant in the home-cage is not efficient in reversing long-term behavioral effects of cocaine sensitization (Gerdeman et al., 2008) , the protocol used in the present study involved treatment with rimonabant in the cocaine-associated environment. Conditioned responses to cocaine-associated cues are mediated by the BLA (Diehl et al., 2013) , with inactivation of this complex prior to the acquisition of cocaine-cue associations blocking the ability of cocainepaired stimuli to elicit conditioned-cued reinstatement (See, 2005) . Thus, the BLA is mainly involved in long-term memory processes resulting from chronic cocaine administration, what is evidenced by the elevated c-Fos expression in chronic compared to acutely cocaine treated animals in the present study. Importantly, the BLA is relatively abundant in CB1 receptors present in GABAergic inhibitory interneurons (Katona et al., 2001) , what could indicate that CB1 receptor blockade in the BLA could have been responsible for the enhanced extinction rates of cocaine conditioned hyperlocomotion in 10 mg/kg rimonabant-treated mice. This would contribute to the blunted effects of cocaine on the expression of behavioral sensitization and to the decrease in BLA c-Fos expression in the Coc-Rim10 group. Blockade of CB1 receptors in GABAergic interneurons would increase GABA transmission within the BLA, thereby inhibiting this brain structure.
It has been previously demonstrated that there is a parallel involvement of the BLA and cortical regions in cocaine-seeking behavior sustained by drug-associated conditioning (for review see Everitt, 2014) . Exposure to a cocaine-associated environment eliciting conditioned hyperlocomotion increases the GABAergic neurotransmission within the mPFC by increasing the excitatory drive from the BLA (Chefer et al., 2011) . Thus, CB1 receptor antagonism would decrease BLA activation and also increase GABAergic neurotransmission within the mPFC, what could have contributed to the suppression of conditioned locomotion to cocaine in the Coc-Rim10 group. In addition, as previously mentioned behavioral sensitization to cocaine is accompanied by a LTD in the NAcc, what seems to be mediated by CB1 receptors. An endocannabinoid-mediated LTD would result from a higher glutamatergic neurotransmission from the mPFC into the NAcc, representing an increased synaptic activity in the mPFC of cocaine sensitized mice that should be effectively inhibited by antagonism of CB1 receptors. In fact, animals previously sensitized to cocaine presented a higher c-Fos expression in the mPFC compared to animals acutely treated with cocaine after a Cocaine Challenge, effect that was reversed by previous treatment with rimonabant.
Finally, mice sensitized to cocaine expressed higher levels of c-Fos protein in the CPu compared to animals being treated with cocaine for the first time. It has been extensively suggested that the transitions from drug use to abuse rely on shifts from ventral to dorsal striatal control over behavior (for review see Everitt, 2014; Everitt and Robbins, 2016) . Initially, drug seeking seems to be a goal-directed behavior, becoming habitual and under the control of the dorsal striatum after extended drug presentation (Zapata et al., 2010) . One drug administration would trigger a firing in mesolimbic dopaminergic neurons that develops into long-term potentiation in the VTA and the NAcc, and via feedback loops would subsequently engage the CPu. Studies with behavioral sensitization corroborate this hypothesis. Parikh et al. (2014) showed that repeated cocaine exposure disrupts presynaptic glutamate neurotransmission and glutamate transporter-mediated clearance mechanisms in the CPu. The authors demonstrated that AMPA glutamate receptors in the CPu are critical for the development of behavioral sensitization, suggesting that such alterations induced by repeated cocaine administration produce an hyperactivation of AMPA receptors in the CPu that would lead to sensitized behavioral response to repeated cocaine (Parikh et al., 2014) . Furthermore, an over activation of glutamate signaling in the dorsal striatum seems to mediate the behavioral sensitization effects of repeated cocaine exposure.
The mediation of drug-associated conditioned reinforcement by the NAcc depends upon its afferents from the amygdala (Cardinal et al., 2002) . Thus, Everitt and Robbins (2016) proposed that glutamatergic BLA transmission might influence habitual instrumental behavior in the CPu through projections into the NAcc (Wright et al., 1996) . Although the specific mechanisms linking the amygdala to the dorsal striatum remain unknown, the present findings suggest that the inhibition of long-term cocaine behavioral effects requires the decrease of neural activity within both the BLA and the CPu, and that these effects can be modulated by CB1 receptors. Disruption of the endocannabinoid system impairs, whereas chronic cannabinoid exposure enhances, dorsal striatum-dependent stimulus-response/habit memory (for review see Goodman and Packard, 2015) . Because the behavioral effects of rimonabant on cocaine-induced behavioral sensitization are contextdependent (Gerdeman et al., 2008) , the CPu also seems to be involved in the BLA-mediated conditioned reinforcing effects of cocaine.
Conclusion
Our findings show that treatment with rimonabant was effective in reversing the long-term behavioral and neuronal effects of chronic cocaine, indicating an important role of the environmental conditioning for endocannabinoid signaling within the brain reward system in the context of cocaine abuse. The present study adds to the evidence that drugs targeting CB1 receptors might be good therapeutic targets for the treatment of cocaine abuse, and suggests that targeting drug-environment associations may be more successful in promoting abstinence and preventing relapse. It is important to emphasize, however, that chronic treatment with high doses of rimonabant may have behavioral depressant effects that could limit its therapeutic usefulness.
